Schreiner MediPharm develops wrap-around labels for Sweden's SHL Medical
The labeling on drug packaging usually starts out as a simple identifier, but now, for autoinjectors and pen injectors (which are often used by patients themselves), it is possible to meet numerous other business or compliance objective. That is some of the thinking that has gone into demonstration projects for SHL Medical (Nacka Strand, Sweden), part of the SHL Group in that country. SHL collaborated with Schreiner MediPharm (US HQ in Blauvelt, NY) to develop multifunction labels that provide educational and compliance goals to the drug sponsor, as well as a platform for attractive branding. With these types of drug-delivery mechanisms—geared toward patients self-injecting, and carrying them with themselves during the day—the package becomes almost an article of personal adornment.
The injectors shown are SHL’s DAI and Molly devices, which are customized to the drug’s delivery requirements. The Schreiner labels feature an anti-slip varnish to improve gripping, a detachable label part for documentation purposes, and both a hologram (a product security feature) and a QR code that can be connected to additional online information. “The specialty labels make customized branding possible and thus emphasize the manufacturers’ brand presentation. Thanks to integrated features the label adds further value,” said Gene Dul, President of Schreiner MediPharm U.S., in a press statement.
Machine Health in Pharmaceutical Production
December 2nd 2024Predictive maintenance in pharmaceutical production can help reduce downtime and increase efficiency. Grundfos Machine Health (GMH) uses artificial intelligence (AI)-driven wireless sensors to monitor motor health in real-time, identifying potential issues. This approach not only reduces maintenance costs but also ensures compliance with industry standards.
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.